Articles tagged with Alzheimer Disease
A recent study examined the association between sleep-disordered breathing and Alzheimer's disease biomarkers in older adults. The research revealed a significant link between the two conditions, with those with sleep-disordered breathing showing higher levels of biomarkers for Alzheimer's disease.
Researchers discovered that an immune reaction in the brain adds fuel to the fire of inflammation, leading to the development of Alzheimer's disease. The microglia cells' activation of inflammasomes makes degradation of Aß proteins more difficult, creating a devastating process.
Lundbeck contributes clinical trial data from over 2,500 patients to CPAD consortium's integrated database. C-Path and Lundbeck aim to expedite the development of new therapies for Alzheimer's disease through public-private partnerships.
A study reveals that Alzheimer risk genes are linked to microglia's response to amyloid-beta, a key protein in the disease. The researchers identified 11 new risk genes that are upregulated when facing increased amyloid-beta levels.
A growing body of evidence suggests that antioxidant treatment in acute ischemic stroke may delay the onset of Alzheimer's dementia. Oxidative stress plays a major role in the pathogenesis of AD, and antioxidants have shown promise in animal models and some clinical trials.
Researchers from University of Konstanz discover that a molecular chaperone helps form Alzheimer fibrils by exposing a vulnerable area on the protein tau, preventing longer, more toxic fibril formation. The findings suggest a possible defense mechanism against Alzheimer's disease.
Researchers discovered that resolvins, specialized lipids, can reduce inflammation and prevent memory loss in a preclinical model of Down syndrome. This finding has the potential to lead to new therapies for Alzheimer's disease, targeting inflammation as a key mechanism in healthy aging.
A new Mayo Clinic study found no link between surgery with general anesthesia and the indicator of Alzheimer's disease. Cortical thinning in cerebral areas was observed, but no significant evidence of amyloid protein deposits, a hallmark of Alzheimer's, was detected.
Researchers have made a groundbreaking finding by using gold nanoparticles to label and visualize amyloid fibrils in their natural state. This breakthrough has significant implications for understanding the mechanisms of Alzheimer's disease and developing new treatments.
A new study by the University of Geneva reveals that elderly individuals with low agreeableness are better protected against Alzheimer's disease. Brain imaging and psycho-cognitive evaluations showed that these individuals have preserved brain regions damaged in normal aging and Alzheimer's disease.
A signaling pathway that helps prevent protein aggregates in brain cells is also required for sleep in fruit flies and zebrafish, suggesting its presence in humans. The study found that suppressing this mechanism led to reduced sleep duration, while overproducing it caused increased sleepiness.
Researchers at University of Pennsylvania School of Medicine found that delivering dantrolene through the nose increases its brain concentration and duration in a mouse model of Alzheimer's disease. The study showed no obvious adverse side effects, paving the way for potential long-term treatment options.
A new preclinical study reveals that a lack of BIN1 leads to defective neurotransmitter transmission, impairing brain cell communication and memory consolidation. The study suggests that BIN1 plays a crucial role in regulating synaptic transmission and may be involved in the progression of Alzheimer's disease.
Scientists have identified a specific antibody that binds to brain immune cells and triggers processes that enhance microglia activity. This stimulates the immune cells to detect and degrade abnormal protein deposits, known as plaques, more effectively, potentially providing better protection against Alzheimer's disease.
Researchers from the University of South Australia have developed a nano formulation that increases curcumin's oral bioavailability by 117%, paving the way for clinical trials for Alzheimer's. The delivery method also shows promise in preventing genital herpes, with curcumin able to stop the virus and reduce inflammation.
Researchers found that interferon triggers a cascade of inflammatory reactions leading to synapse loss and neuronal dysfunction in Alzheimer's disease. The study also suggests that blocking the IFN-triggered cascade could potentially reduce microglia activation and synapse loss.
Researchers will focus on brain regions where place, time and memory occur to understand Alzheimer's disease. The goal is to identify early mechanisms of the disease and develop an early diagnosis.
Researchers developed a small molecule that can modify the coordination sphere of copper bound to amyloid-β, inhibiting its aggregation and toxicity. The study offers insights into chemically modifying neurotoxicity in Alzheimer's disease.
A Mayo Clinic study found that genetic variants on chromosomes 1 and 5 were linked to higher tau levels in older adults. Participants with these variants had about 10% higher tau levels than those without them. The research suggests that genes previously linked to Alzheimer's risk may not be associated with tau accumulation.
A study of 754 participants found that specific gene variants on chromosomes 1 and 5 were associated with higher levels of tau protein in the brain. These variants were present in around 2-3% of the group, leading to about 10% higher tau levels than those without.
Researchers have identified a link between L-serine and memory problems in Alzheimer's disease. Supplying this amino acid as a nutritional supplement restored spatial memory affected early in mouse models.
A blood test measuring phosphorylated tau 181 (pTau181) shows promise in detecting Alzheimer's disease and mild cognitive impairment. The test's accuracy surpasses existing methods, offering a potential solution for early diagnosis and treatment.
A new blood test detects abnormal tau protein accumulation, differentiating healthy participants from those with Alzheimer's pathology and predicting disease progression. The test shows promise for early detection and diagnosis of Alzheimer's disease and related neurodegenerative disorders.
Researchers at the Gladstone Institutes report that reducing levels of tau protein prevents core autism symptoms, seizures, and other abnormalities in mouse models. The findings suggest promise as a potential treatment for some forms of autism.
Scientists have detected a potential new biomarker for Alzheimer's disease in the Presenilin1 gene, which shows promise for earlier diagnosis and treatment. The study found that changes in DNA methylation of this gene are common in people with Alzheimer's and could be used to monitor environmental triggers and treatment responses.
A new study has found that the loss of RNA editing in the brain may contribute to the development of Alzheimer's disease. The research, published in Molecular Brain, replicated this process in mice and discovered it led to the loss of synapses, a key feature of the disease.
Conserved epigenetic regulators BAZ2B and EHMT1 identified as novel anti-aging targets in aging research. The study reveals a mechanism for regulating cognitive aging by reducing mitochondrial function.
A new study found that widowhood can lead to a sharper cognitive decline in older adults, particularly those with high beta-amyloid levels. This effect was observed even after controlling for other factors such as age, sex, and socioeconomic status.
Dr. Silvia Fossati, a Temple University Health System researcher, has been awarded a $500,000 grant to develop an Alzheimer's-specific version of a carbonic anhydrase inhibitor drug family. The goal is to target mitochondrial dysfunction, amyloid protein build-up, and inflammation in the brain, which are hallmarks of Alzheimer's disease.
A University of Houston researcher is increasing health literacy among Hispanics/Latinos to address the significant disparities in Alzheimer's disease development and treatment. The largest ethnic minority group in the US, H/Ls are 50% more likely to develop AD, yet they comprise less than 1% of clinical trials.
A study by the American Academy of Neurology found that increased out-of-pocket costs for neurologic medications, such as Alzheimer's disease and Parkinson's disease, are associated with lower patient adherence. For example, a $50 increase in cost was linked to a 12% decrease in medication possession ratio for Alzheimer's disease.
A study by FAU researchers found that neighborhood environments with greater access to social, walking and retail destinations may have limited cognitive benefits for APOE ε2 carriers, who are at lower risk for Alzheimer's disease. Beneficial neighborhoods can provide spaces for exercise, mental stimulation and stress reduction.
A University of South Florida study suggests beta-arrestin-2 can lead to increased accumulation of neurotoxic tau tangles in the brain, causing forms of dementia. The researchers found that oligomerized beta-arrestin-2 disrupts protective clearance processes, leading to disease-causing tau buildup.
The number of people with dementia in Europe is estimated to almost double by 2050, from 7.9 million to 14.3 million, according to a new report by Alzheimer Europe. The prevalence of dementia has decreased in recent years, but this trend is expected to reverse unless better treatments and prevention strategies are developed.
Scientists have discovered a novel gold nanocluster that can inhibit Aβ monomer formation, dissolve preformed fibrils and restore conformation of peptides. The nanocluster also has good biocompatibility and infiltration ability across the blood-brain barrier.
Researchers found that subtle differences in cognitive performance can predict the progression of Alzheimer's disease, even before abnormal levels of beta-amyloid plaques accumulate. Low-cost, non-invasive cognitive testing can identify at-risk individuals, making them ideal candidates for therapeutic intervention and clinical trials.
Researchers found that bilingual individuals had a shorter conversion time from mild cognitive impairment to Alzheimer's disease than monolinguals. Despite this, bilinguals still experienced a faster decline once diagnosed with the disease.
Higher ratios of very-long-chain to long-chain ceramides were associated with reduced dementia and Alzheimer's disease risks, suggesting a potential role for plasma ceramides as biomarkers. Elevated ceramide ratios may also have protective effects against dementia, while altered lipid metabolism is linked to its development.
A study published in the Journal of Psychiatric Research has identified a brain circuit that could indicate the risk of developing Alzheimer's. Researchers discovered that poor connectivity between the brainstem and cerebellum may be predictive of Alzheimer's risk, specifically targeting those with a family history.
A new blood test uses a carbon nanotube-based sensor to detect Alzheimer's disease with high accuracy, measuring key biomarkers in human plasma. The test achieved an average sensitivity of 90.0% and selectivity of 90.0%, outperforming conventional biosensors.
New research found that the accumulation of tau and amyloid proteins in the brain significantly alters gene expression, particularly in genes related to inflammation. The study provides new insights into the progression of Alzheimer's disease and highlights potential pathways for treatment.
A phase 2/3 clinical trial evaluating two investigational drugs for their ability to slow memory loss and cognitive decline in people with a rare, inherited form of Alzheimer's disease did not meet its primary outcome. Despite disappointing results, the researchers continue to explore data from the trial's cognitive and clinical outcomes.
A global initiative aims to harness digital data and wearable technologies to detect neurodegenerative diseases like Alzheimer's. The project, backed by Bill Gates and £100m investment goal, will develop 'fingerprints' of disease that can be detected early.
Michigan State University research found that optimistic partners contribute to their spouses' health, staving off cognitive decline and Alzheimer's disease. Couples who share healthy habits and positive memories together experience improved well-being.
A team of researchers at Wake Forest School of Medicine will use a novel brain-imaging technique to image microtubules in the brain, which could potentially predict the onset of Alzheimer's disease. The study aims to identify a biomarker for neural degeneration and cognitive impairment.
Researchers analyzed brain tissue from patients with Alzheimer's and corticobasal degeneration, finding that modifications to the tau protein influence its misfolding behavior. The study reveals key insights into how tau filaments form, grow, and spread throughout the brain, potentially accelerating the fight against neurodegenerative ...
Physically active older adults experience reduced risks of early death, breast and prostate cancer, fractures, and dementia. Physical activity also promotes healthier ageing trajectories, better quality of life, and improved cognitive functioning.
Researchers at NYU Abu Dhabi have designed proteins called cell-penetrating peptides (CPPs) that prevent the aggregation of amyloid-β protein associated with Alzheimer's disease. The CPPs stabilize Aβ in a non-aggregated state, inhibiting neurotoxicity and protecting neurons from damage.
Researchers found that people with Parkinson's carrying APOE4 variant experience faster cognitive decline and more severe dementia. Targeting APOE may reduce dementia risk in Parkinson's patients.
A DNA study of over 10,000 people has identified naturally occurring gene variants that reduce the risk of Alzheimer's disease by impairing tyrosine phosphatase activity and cell survival. The findings suggest PI3K/Akt/GSK-3β signalling pathway as a key target for therapeutic drugs.
Scientists at U-M identified distinct excitatory neurons in the retrosplenial cortex, which can continuously encode direction-related information over long durations. These low rheobase neurons are ideal for navigation, providing persistent sense of direction that complements other brain signals.
Regular aerobic exercise training improves brain glucose metabolism and higher-order thinking abilities, including executive function. The study suggests that exercise can potentially enhance brain and cognitive functions that are sensitive to Alzheimer's disease.
Researchers discovered that exposure to flickering light at 40 Hz causes brains to release signaling chemicals that may help fight Alzheimer's disease. The study found a surge of cytokines and phosphoproteins, which could support neural health and activate microglia to clean up amyloid beta plaques.
A multicenter study has identified a new biomarker for vascular dementia, lipocalin 2 protein, found in cerebrospinal fluid. The protein's presence can discriminate between vascular dementia and Alzheimer's disease.
Researchers at Arizona State University have developed a new method called TREE to edit genes implicated in Alzheimer's disease, achieving 90% efficiency in human stem cells. The breakthrough uses base editors to make single DNA edits with high accuracy, paving the way for personalized medicine and disease modeling.
A new study suggests that people who consume higher amounts of the antioxidant flavonol are less likely to develop Alzheimer's dementia. The research, which followed 921 participants for six years, found that those with higher flavonol intake had a 48% lower risk of developing the disease.
A study published in Environmental Health found a link between air pollution from traffic and an increased risk of developing dementia, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Living near green spaces appears to have protective effects against these neurological disorders.
Researchers found that reelin promotes synaptic plasticity and reduces Tau phosphorylation in animal models with tauopathy, potentially reducing neurodegenerative effects. This discovery opens a new perspective for designing future therapeutic targets to combat Alzheimer's and other tauopathies.
Researchers at Cold Spring Harbor Laboratory have developed a chemical compound, UBP1700, that inhibits certain NMDARs while allowing others to function. This allows for the precise investigation of NMDAR activity in both healthy and diseased brains.
A novel pharmacological chaperone has been shown to restore levels of the sorting molecule VPS35 and prevent the accumulation of abnormal proteins in mice with Alzheimer's disease. This treatment approach has been proven to improve memory and learning, reducing tau tangles and amyloid-beta plaques.